Diagnostic and prognostic role of LINC01767 in hepatocellular carcinoma

Figure 2 LINC01767 was downregulated and was potential diagnostic and prognostic marker in hepatocellular carcinoma. A: A total of 3529 up regulated and 250 down regulated long noncoding RNAs were identified; B: The LINC01767 caught our attention with a log fold change -1.575 and P < 0.0001; C: Deferential expression of LINC01767 in Gene Expression Omnibus dataset; D: LINC01767 downregulated in GSE78160; E: LINC01767 downregulated GSE58043; F: LINC01767 downregulated GSE84005; G: Receiver-operating characteristic (ROC) curves of LINC01767 in The Cancer Genome Atlas (TCGA); H: The LINC01767 expression level stand as a predictor for overall survival (OS) (P = 0.016); I: The nomogram model including T/N/Residual tumor, vascular invasion, body mass index and LINC01767; J: The calibration curve showed that there was good concordance between the predicted and observed values of 1-year and 3-year OS; K: Area under the curve (AUC) of 3-year accuracy was 0.71 [95% confidence interval (CI): 0.82-0.60], the AUC of 5-year accuracy was 0.67 (95%CI: 0.79-0.55) with a good prediction performance; L: Showed the high-risk score group of TCGA having a worse prognosis with median survival time 2398 d comparing 2752 d in low risk group with hazard ratio = 2.71 (95%CI: 1.51-4.89, P = 5.6e-4); M-O: The nomogram model showed a better DCA performance than sole LINC01767 with greater than line 0. TCGA: The Cancer Genome Atlas; FC: Fold change; lncRNA: Long non-coding RNA.